A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

Part of paid clinical trials in Los Angeles, California.

Sponsor
Genentech, Inc.
Study ID
NCT00873756
Phase
PHASE1
Status
Completed

Conditions

  • Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • FOLFOX regimen — DRUG
    Intravenous repeating dose
  • bevacizumab — DRUG
    Intravenous repeating dose
  • dulanermin — DRUG
    Intravenous repeating dose

Study Details

This is a multicenter, open-label study enrolling a total of up to 23 patients.

Key Dates

First listed
Apr 2, 2009
Start date
May 31, 2009
Status verified
Nov 2016
Primary completion
Mar 31, 2014
Completion
Apr 30, 2014

Study Design

Enrollment
23 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: A

Primary Outcome Measure

Incidence and nature of dose-limiting toxicities [ Time Frame: Until study discontinuation or the end of Cycle 26 ]

Locations (7)

FacilityCityStateZIPSite coordinators
-Los AngelesCalifornia90095-
-San FranciscoCalifornia94115-
-AuroraColorado80045-
-Fort CollinsColorado80528-
-HarveyIllinois60426-
-AlbuquerqueNew Mexico87131-
-Chapel HillNorth Carolina27599-

Related Studies